ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
